Home > Insider Trading > Filing (0000899243-21-028253)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1403752	Zymeworks Inc.	ZYME	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1761853	Ali Tehrani	C/O Zymeworks Inc. 1385 West 8Th Avenue, Suite 540 Vancouver A1 V6H 3V9	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2021-07-12	12,669	$4.31	272,994	No	4	M	Direct
Common Shares	Disposition	2021-07-12	12,669	$36.12	260,325	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2021-07-12	12,669	$0.00	12,669	$4.31

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
44,991	2013-01-01	2022-01-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	55,511	Indirect	Held by spouse

Footnotes

Pursuant to a 10b5-1 plan entered into May 13, 2021.
The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.3062 using the Bank of Canada exchange rate for July 12, 2021 (CAD1.00 = $0.8019).
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.0649 to $36.5902, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 12, 2021 at each separate price.
Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of January 1, 2012 and (ii) remainder of underlying shares in 36 equal monthly installments on the last day of month following first anniversary of grant date.